Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects as determined by the screening procedure * Signed written informed consent form in accordance with good clinical practice (GCP) and local legislation was available * Age ≥ 18 and ≤ 40 years * Body mass index: BMI ≥ 18 and ≤ 29.9 kg/m2 * Normal findings in medical history and physical examination unless the investigator considered an abnormality to be clinically irrelevant * Normal laboratory parameters unless the investigator considered an abnormality to be clinically irrelevant Exclusion Criteria: * Any finding in the medical examination (including blood pressure, pulse rate, ECG, and laboratory parameters) deviating from normal and of clinical relevance * History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, autoimmune, hormonal disorders, diseases of the central nervous system (such as epilepsy), or psychiatric disorders * Symptoms of a clinically relevant illness in the 3 weeks before the first trial day * History of orthostatic hypotension, fainting spells, and blackouts * Chronic or relevant acute infections * History of allergy / hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator * History of * any bleeding disorder including prolonged or habitual bleeding * any familial bleeding disorder * other haematological disease * cerebral bleeding (e.g. after a car accident) * commotio cerebri * Hereditary deficiency of protein C or S, or a mutation of factor V (Leiden), or any other known abnormality affecting coagulation, fibrinolysis, or platelet function * Platelet count \< 150000/μL * Any ECG value outside of the reference range of clinical relevance (QRS interval \> 110 ms or QTcB (QT interval Bazett correction) \> 450 ms will be an obligatory exclusion criterion) * Intake of drugs with a long half-life (\> 24 hours) within 1 month prior to administration * Use of any drugs that might influence the results of the trial within 10 days prior to administration or during the trial * Participation in another trial with an investigational drug within 2 months prior to administration or during trial * Participation in an LPS trial within the last six weeks * Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days * Concurrent or history of drug, alcohol, tobacco or coffee / tea / cola abuse * Blood donation within 1 month prior to administration or during the trial * Excessive physical activities within 5 days prior to administration or during the trial * Seropositivity for hepatitis B surface antigen (HBs-Ag), hepatitis C virus (HCV), HIV 1, or HIV 2 antibodies * Weight over 95 kg